A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408.

Andrew M EvensFangxin HongThomas M HabermannRanjana H AdvaniRandy D GascoyneThomas E WitzigAndrew QuonErik A RanheimStephen M AnsellPuneet Singh CheemaPhilip A DyTimothy E O'BrienJane N WinterTerrence P CesconJulie E ChangBrad S Kahl

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Altogether, neither bortezomib added to BR induction nor lenalidomide added to rituximab maintenance immediately post-BR induction is recommended in untreated FL.

Keyphrases

multiple myeloma
chronic lymphocytic leukemia
phase ii study
newly diagnosed
open label
diffuse large b cell lymphoma
placebo controlled
double blind
stem cell transplantation
locally advanced
hodgkin lymphoma
phase ii
phase iii
study protocol